|
Match
|
Document |
Document Title |
|
|
US20130095177 |
METHOD OF PREPARING AN ORAL DOSAGE FORM COMPRISING FINGOLIMOD
The present invention relates to a method of preparing an intermediate containing fingolimod, a method of preparing granules containing fingolimod, a method of preparing an oral dosage form...
|
|
|
US20110059170 |
METHODS FOR ADMINISTERING WEIGHT LOSS MEDICATIONS
Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the...
|
|
|
US20120148671 |
GASTRIC RETAINED GABAPENTIN DOSAGE FORM
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
|
|
|
US20120207828 |
LARGE DOSE RIBAVIRIN FORMULATIONS
The present invention is related to pharmaceutical dosage forms of ribavirin which are designed to increase patient compliance to a ribavirin therapy. Examples of such dosage forms include 400 mg...
|
|
|
US20120189693 |
ORAL DOSAGE FORMS
Aspects of the present invention are directed to oral dosage forms comprising a compressed microtablet, wherein said microtablet has a major dimension that is between about 0.25 mm and about 1.0 mm...
|
|
|
US20110091545 |
Direct Injection moldable and rapidly disintegrating tablet matrix
The present invention relates to a novel directly compressible matrix for the production of tablets which disintegrate rapidly in the presence of moisture, in particular in the mouth.
|
|
|
US20130101670 |
FORMULATIONS COMPRISING COATED FINE PARTICLES
[OBJECT] To provide an intraorally rapidly disintegrating tablet comprising 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxyli
c acid as an active ingredient, which is a formulation that...
|
|
|
US20120171286 |
METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF STATIN-INDUCED MYOPATHY
Disclosed are methods for treating or preventing a statin-mediated myopathy in a subject via administration of a therapeutically effective amount of a geranylgeranylation activator. Further...
|
|
|
US20110217372 |
Fast dissolving oral tablets and method for production thereof
Provided is a fast dissolving oral tablet, and a method for the production thereof, including the steps of: compressing a mixture of active ingredients, pharmaceutically acceptable additives, and...
|
|
|
US20080175905 |
ESTROGEN/SERM AND ESTROGEN/PROGESTIN BI-LAYER TABLETS
The present invention is directed to bi-layer tablets comprising at least one estrogen in a first layer and a therapeutic agent in a second layer, and processes for their preparation.
|
|
|
US20110091544 |
Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
Small tablets for use in procedural sedation, anxiolysis and analgesia comprising the combination sufentanil and triazolam administered via the oral transmucosal route and methods for using the...
|
|
|
US20120135069 |
NANONIZED TESTOSTERON FORMULATIONS FOR IMPROVED BIOAVAILABILITY
Nanonized formulations of testosterone esters, especially testosterone undecanoate, and of testosterone are prepared which show an enhanced oral bioavailability compared to the existing oral...
|
|
|
US20120231075 |
ABUSE-RESISTANT OPIOID DOSAGE FORM
We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix.
|
|
|
US20110020444 |
ABUSE-RESISTANT OPIOID DOSAGE FORM
We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix.
|
|
|
US20130011474 |
MODIFIED AND IMMEDIATE RELEASE FORMULATIONS OF MEMANTINE
The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing...
|
|
|
US20110064805 |
Porous cellulose aggregate and molding composition thereof
A porous cellulose aggregate characterized by having a secondary aggregate structure resulting from aggregation of primary cellulose particles, having a pore volume within a particle of 0.265 to...
|
|
|
US20110038927 |
CONTROLLED RELEASE HYDROCODONE FORMULATIONS
A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof,...
|
|
|
US20120034301 |
TABLET AND PESTLE THEREFOR
A tablet which comprises solid particles, especially magnesium oxide particles as the main component and has excellent shape retentivity with extremely low susceptibility to wearing and chipping....
|
|
|
US20130011476 |
STABLE COMPOSITIONS OF FAMOTIDINE AND IBUPROFEN
Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface...
|
|
|
US20130011475 |
STABLE COMPOSITIONS OF FAMOTIDINE AND IBUPROFEN
Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface...
|
|
|
US20120156292 |
STABLE COMPOSITIONS OF FAMOTIDINE AND IBUPROFEN
Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface...
|
|
|
US20120156291 |
STABLE COMPOSITIONS OF FAMOTIDINE AND IBUPROFEN
Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface...
|
|
|
US20120164218 |
SOLID DOSAGE FORMS OF VALSARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE AND METHOD OF MAKING THE SAME
Monolayer, bilayer and trilayer solid dosage forms of a combination of valsartan, amlodipine and hydrochlorothiazide are made.
|
|
|
US20120177733 |
SOLID DOSAGE FORMS OF VALSARTAN AND AMLODIPINE AND METHOD OF MAKING THE SAME
Monolayer and bilayer solid dosage forms of a combination of valsartan and amlodipine are made.
|
|
|
US20100303906 |
SOLID DOSAGE FORMS OF VALSARTAN AND AMLODIPINE AND METHOD OF MAKING SAME
Monolayer and bilayer solid dosage forms of a combination of valsartan and amlodipine are made.
|
|
|
US20120183606 |
DRUG DELIVERY SYSTEM COMPRISING POLYOXAZOLINE AND A BIOACTIVE AGENT
The invention relates to drug delivery systems comprising a water-soluble polymer matrix and a bioactive agent entrained therein, said water soluble polymer matrix containing at least 50 wt. % of...
|
|
|
US20120195965 |
SOLID DOSAGE FORM COMPRISING A FIBRATE
The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in an non-aqueous vehicle in order to...
|
|
|
US20110311622 |
METHOD FOR ADDING SENSORY CONDITIONING CUES IN A PHARMACOTHERAPEUTIC REGIMEN
A method for administering pharmaceutical agents to a subject is provided. The method includes the steps of: a) providing a course of treatment for a subject, which course includes periodically...
|
|
|
US20120009257 |
Galenical Formulations of a Fixed Dose Combination of Valsartan and Aliskiren
The invention provides a pharmaceutical oral fixed dose combination of aliskiren and valsartan. Aliskiren is shown to slow the dissolution rate of valsartan and the resultant undesirable gelling of...
|
|
|
US20110268798 |
ORALLY DISNTEGRATING TABLETS FOR THE TREATMENT OF PAIN
An orally disintegrating tablet comprising acetylsalicylic acid, acetaminophen and caffeine and one or more pharmaceutically acceptable excipients.
|
|
|
US20120135075 |
DOSAGE FORM
The present invention provides a dosage form, particularly a tamper resistant dosage form, comprising: melt-extruded particulates comprising a drug; and a matrix; wherein said melt-extruded...
|
|
|
US20060188566 |
Nanoparticulate formulations of docetaxel and analogues thereof
Described are nanoparticulate docetaxel or analogue thereof compositions. The compositions, which comprise a nanoparticulate docetaxel or analogue thereof and at least one surface stabilizer, can...
|
|
|
US20130039981 |
Quick Dissolving, Long Acting Zinc Therapeutic Formulations
The present invention comprises a quick dissolving, long acting zinc therapeutic cold formulation containing high levels of an active compound encapsulated within bioadhesive/muco-adhesive polymers...
|
|
|
US20130011479 |
DOUBLE-LAYER PHARMACEUTICAL FORMULATIONS CONTAINING OPIOID AGONISTS AND ANTAGONISTS
Immediate-release formulations are described, consisting of double-layer tablets wherein one layers contains an opioid agonist and the other an opioid antagonist.
|
|
|
US20130089607 |
ONCE DAILY TROSPIUM CHLORIDE TREATMENT METHOD
A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum...
|
|
|
US20110295151 |
Enteroendocrine Manipulation for Metabolic Effect
L-cells may be introduced in the gastrointestinal tract. L-cells are used in the digestive process to produce a more efficient and lasting means of regulating feelings of satiation in a patient....
|
|
|
US20130089603 |
COMPOSITIONS AND METHODS FOR TREATING OBESITY AND OBESITY-RELATED CONDITIONS
A method to effectively treat the adverse events of ingested lipase inhibitor such as orlistat, and to maintain the effectiveness of ingested orlistat, the method comprising the steps of: ingesting...
|
|
|
US20050202083 |
Storage stable tablets of fosinopril sodium
The technical field of the present invention relates to the selection of lubricants to provide a storage stable tablet of fosinopril, alone or in combination with a diuretic, as well as processes...
|
|
|
US20120027864 |
COATED DRUG DELIVERY FORMULATIONS
The invention relates generally to methods of making formulations for delivering biological agents to a patient. In one aspect, proliposomal drug-delivery systems for medicaments are provided. In...
|
|
|
US20120213847 |
MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA
The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate...
|
|
|
US20110212169 |
METHOD FOR PRODUCING POWDER CONTAINING NANOPARTICULATED SPARINGLY SOLUBLE DRUG, POWDER PRODUCED THEREBY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME (As Amended)
Disclosed are a method for preparing a powder containing a nanoparticulated sparingly soluble drug, a powder prepared thereby, and a pharmaceutical composition containing the same. The disclosed...
|
|
|
US20120048764 |
PROCESS TO FORM AN ORALLY DISINTEGRATING TABLET FOR HUMAN USE
The present invention pertains to a process for the preparation of an orally disintegrating tablet for administration to a human subject, the tablet containing a medicinal substance to treat a...
|
|
|
US20080279933 |
FLURBIPROFEN AND MUSCLE RELAXANT COMBINATIONS
This invention is a novel pharmaceutical composition comprising flurbiprofen or a pharmaceutically acceptable salt thereof in combination with an α-2 adrenergic receptor agonist or a ...
|
|
|
US20110318411 |
MULTI-LAYERED ORALLY DISINTEGRATING TABLET AND THE MANUFACTURE THEREOF
The present invention features a tablet containing a first layer and a second layer, wherein: (i) the first layer includes a pharmaceutically active agent and the composition of the first layer is...
|
|
|
US20130115287 |
INTRAORALLY DISINTEGRATING TABLET
Disclosed is an orally disintegrating tablet which masks bitterness, dissolves well, and which permanently retains good oral disintegration properties immediately following manufacture. The...
|
|
|
US20060115528 |
Rapidly disintegrating tablet
The present invention relates to rapidly disintegrating tablets intended to be used as orodispersible tablets or dispersible tablets. They are ingested either by dispersing directly in the mouth or...
|
|
|
US20120225121 |
BIOEQUIVALENT FORMULATION OF EFAVIRENZ
The present invention provides a suitable technique namely wet milling and the process for reducing the particle size of efavirenz and making a tablet or capsule formulation with desired...
|
|
|
US20080085307 |
Paired/matched medication
This patent pairs/matches medication components. This may help with more accurate dosing when the need arises to split tablets. Also there may be increased patient compliance with patients taking...
|
|
|
US20070141144 |
Oral delivery system
The present invention relates generally to formulations comprising paracetamol. More particularly, the present invention provides a swallow formulation comprising paracetamol which facilitates the...
|
|
|
US20120012499 |
TABLET FORMULATION
The present invention relates to a pharmaceutical fixed dose combination tablet comprising repaglinide and metformin. The present invention also provides a method of producing said tablet.
|